Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on January 22, 2026. The company, incorporated in Delaware and headquartered in Dallas, Texas, operates in the pharmaceutical sector with a specific focus on rare cancers. The filing serves as a Regulation FD disclosure regarding a corporate event held on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the demonstration of new technology rather than a change in financial status.
Guidance, Outlook, and Management Commentary
- Event Details: On January 22, 2026, the Company hosted an event to discuss and demonstrate initial AI tools and a multi-agentic system.
- Focus Area: The demonstrated technology is specifically focused on rare cancers.
- Exhibit Reference: A presentation detailing these tools is included as Exhibit 99.1.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Key Facts for Investor Verification
- Verify the technical capabilities and development stage of the AI tools and multi-agentic system described in Exhibit 99.1.
- Confirm the timeline for potential clinical application or commercialization of the rare cancer-focused AI tools.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Monitor future filings for any updates on the regulatory or strategic implications of the demonstrated AI technology.